

Mapping Psilocybin-Assisted Therapies: A Scoping Review

Supplemental Information:

1. References — Full Text Reviews
2. Electronic Search Strategy

References — Full Text Review Articles

Appendix: Scoping Review Publication References (Full Text Review)

- (222) Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. *Journal of Psychopharmacology*, 29(3), 289–299. <https://doi.org/10.1177/0269881114565144>
- (829) Bogenschutz, M. P. (2015). Mood, Craving, and Self-efficacy in Psilocybin-Assisted Treatment of Alcoholism. *Neuropsychopharmacology*, 40, S90. <https://doi.org/10.1038/npp.2015.324>
- (1108) Bogenschutz, M., Forcehimes, A., Pommy, J., Wilcox, C., Bigelow, R., & Barbosa, P. (2014). A pilot study of psilocybin-assisted treatment for alcohol dependence: Acute effects and short-term alcohol use self-efficacy, and craving: 0618. *Alcoholism: Clinical & Experimental Research*, 38. Retrieved from [insights.ovid.com](https://www.ovid.com)
- (302) Nielson, E. M., May, D. G., Forcehimes, A. A., & Bogenschutz, M. P. (2018). The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions. *Frontiers in Pharmacology*, 9, 132. <https://doi.org/10.3389/fphar.2018.00132>
- (305) Bogenschutz, M. P., Podrebarac, S. K., Duane, J. H., Amegadzie, S. S., Malone, T. C., Owens, L. T., ... Mennenga, S. E. (2018). Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder. *Frontiers in Pharmacology*, 9. <https://doi.org/10.3389/fphar.2018.00100>
- (1002) Amegadzie, S., Mennenga, S., Podrebarac, S., Duane, H., Ross, S., Bogenschutz, M. (2018). Psilocybin-assisted treatment for alcohol use disorder: a clinical perspective. *American Journal on Addictions*, 27(4), 317. [10.1111/ajad.12753](https://doi.org/10.1111/ajad.12753)
- (176) Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011). Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. *Archives of General Psychiatry*, 68(1), 71–78. <https://doi.org/10.1001/archgenpsychiatry.2010.116>
- (579) Grob, C. (2012). Psilocybin treatment for anxiety in patients with advanced-stage cancer. *Neuropsychopharmacology*, 38(SUPPL.1), S15.
- (149) Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006). Safety,

tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. *The Journal of Clinical Psychiatry*, 67(11), 1735–1740.

(1619) Moreno, F., Wiegand, C. B., Delgado, P. L., Taitano, K. (2003). Safety, tolerability, and efficacy of psilocybin in treatment-refractory obsessive-compulsive disorder: Preliminary findings. *Biological Psychiatry*, 53(8), 46S.

(216) Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT_{2A}R agonist psilocybin in the treatment of tobacco addiction. *Journal of Psychopharmacology (Oxford, England)*, 28(11), 983–992. <https://doi.org/10.1177/0269881114548296>

(245) Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017). Long-term follow-up of psilocybin-facilitated smoking cessation. *The American Journal of Drug and Alcohol Abuse*, 43(1), 55–60. <https://doi.org/10.3109/00952990.2016.1170135>

(311) Noorani, T., Garcia-Romeu, A., Swift, T. C., Griffiths, R. R., & Johnson, M. W. (2018). Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. *Journal of Psychopharmacology (Oxford, England)*, 32(7), 756–769. <https://doi.org/10.1177/0269881118780612>

(835) Garcia-Romeu, A. P., Noorani, T., Griffiths, R. R., Johnson, M. W. (2015). Long-term follow-up of psilocybin-facilitated smoking cessation: Abstinence outcomes and qualitative analysis of participant accounts. *Drug and Alcohol Dependence*, 156, e78. [10.1016/j.drugalcdep.2015.07.1130](https://doi.org/10.1016/j.drugalcdep.2015.07.1130)

(220) Garcia-Romeu, A., Griffiths, R. R., & Johnson, M. W. (2015). Psilocybin-occasioned Mystical Experiences in the Treatment of Tobacco Addiction. *Current Drug Abuse Reviews*, 7(3), 157–164.

(216) Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., ... Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. *Journal of Psychopharmacology (Oxford, England)*, 30(12), 1181–1197. <https://doi.org/10.1177/0269881116675513>

(830) Griffiths, R. (2015). A single dose of psilocybin produces substantial and enduring decreases in anxiety and depression in patients with a life-threatening cancer diagnosis: A randomized double-blind trial. *Neuropsychopharmacology*, 40(SUPPL.1), S90-S91. [10.1038/npp.2015.324](https://doi.org/10.1038/npp.2015.324)

(270) Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., ... Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. *Journal of Psychopharmacology (Oxford, England)*, 30(12), 1165–1180. <https://doi.org/10.1177/0269881116675512>

(306) Malone, T. C., Mennenga, S. E., Guss, J., Podrebarac, S. K., Owens, L. T., Bossis, A. P.,

... Ross, S. (2018). Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy. *Frontiers in Pharmacology*, 9. <https://doi.org/10.3389/fphar.2018.00256>

(1110) Sevanick, L. (2014). Psilocybin-assisted psychotherapy in the treatment of cancer-related psychosocial distress/anxiety. *Psycho-Oncology*, 23(SUPPL.1), 73-74. 10.1002/pon.3478

(1354) Swift, T. C., Belser, A. B., Agin-Liebes, G., Devenot, N., Terrana, S., Friedman, H. L., ... Ross, S. (2017). Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Distress. *Journal of Humanistic Psychology*, 57(5), 488–519. <https://doi.org/10.1177/0022167817715966>

(1344) Belser, A. B., Agin-Liebes, G., Swift, T. C., Terrana, S., Devenot, N., Friedman, H. L., ... Ross, S. (2017). Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis. *Journal of Humanistic Psychology*, 57(4), 354–388. <https://doi.org/10.1177/0022167817706884>

(235) Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., ... Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. *The Lancet Psychiatry*, 3(7), 619–627. [https://doi.org/10.1016/S2215-0366\(16\)30065-7](https://doi.org/10.1016/S2215-0366(16)30065-7)

(831) Carhart-Harris, R. (2015). Results: Of a multi-modal neuroimaging study of LSD and a psilocybin for treatment-resistant depression clinical trial. *Neuropsychopharmacology*, 40(SUPPL.1), S91-S92. 10.1038/npp.2015.324

(863) Carhart-Harris, R. (2016). 5-HT_{2A} agonist drugs as new treatments in psychiatry. *European Neuropsychopharmacology*, 26(Supplement 2), S121.

(300) Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., ... Nutt, D. J. (2017). Psilocybin for treatment-resistant depression: FMRI-measured brain mechanisms. *Scientific Reports*, 7(1), 13187. <https://doi.org/10.1038/s41598-017-13282-7>

(326) Kaelen, M., Giribaldi, B., Raine, J., Evans, L., Timmerman, C., Rodriguez, N., ... Carhart-Harris, R. (2018). The hidden therapist: Evidence for a central role of music in psychedelic therapy. *Psychopharmacology*, 235(2), 505–519. <https://doi.org/10.1007/s00213-017-4820-5>

(313) Lyons, T., & Carhart-Harris, R. L. (2018). Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. *Journal of Psychopharmacology*, 32(7), 811–819. <https://doi.org/10.1177/0269881117748902>

(321) Lyons, T., & Carhart-Harris, R. L. (2018). More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression. *Frontiers in Psychology*, 9. <https://doi.org/10.3389/fpsyg.2018.01721>

(945) Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018). Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. *Frontiers in Pharmacology*, 8. <https://doi.org/10.3389/fphar.2017.00974>

(323) Stroud, J. B., Freeman, T. P., Leech, R., Hindocha, C., Lawn, W., Nutt, D. J., ... Carhart-

Harris, R. L. (2018). Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. *Psychopharmacology*, 235(2), 459–466. <https://doi.org/10.1007/s00213-017-4754-y>

(329) Erritzoe, D., Roseman, L., Nour, M. M., MacLean, K., Kaelen, M., Nutt, D. J., & Carhart-Harris, R. L. (2018). Effects of psilocybin therapy on personality structure. *Acta Psychiatrica Scandinavica*, 138(5), 368–378. <https://doi.org/10.1111/acps.12904>

(1355) Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017). Patients' Accounts of Increased "Connectedness" and "Acceptance" After Psilocybin for Treatment-Resistant Depression. *Journal of Humanistic Psychology*, 57(5), 520–564. <https://doi.org/10.1177/0022167817709585>

(332) Roseman, L., Demetriou, L., Wall, M. B., Nutt, D. J., & Carhart-Harris, R. L. (2018). Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. *Neuropharmacology*, 142, 263–269. <https://doi.org/10.1016/j.neuropharm.2017.12.041>

(324) Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., ... Nutt, D. J. (2018). Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. *Psychopharmacology*, 235(2), 399–408. <https://doi.org/10.1007/s00213-017-4771-x>

Appendix 2 Electronic Search Strategy

Ovid MEDLINE(R), Ovid MEDLINE(R) Daily and Epub Ahead of Print, In-Process & Other Non-Indexed Citations 1946 to Present

- 1 Psilocybin/
- 2 psilocybin*.mp.
- 3 indocybin.mp.
- 4 psilocibin*.mp.
- 5 psilocin phosphate ester.mp.
- 6 psilotsibin.mp.
- 7 teonanacatl.mp.
- 8 1 or 2 or 3 or 4 or 5 or 6 or 7
- 9 mood disorders/ or depressive disorder/ or depression, postpartum/ or depressive disorder, major/ or depressive disorder, treatment-resistant/ or dysthymic disorder/ or premenstrual dysphoric disorder/ or seasonal affective disorder/ or cyclothymic disorder/
- 10 depression/
- 11 depressed.mp.
- 12 depression.mp.
- 13 depressive.mp.
- 14 mood.mp.
- 15 affective disorder*.mp.
- 16 anxiety/ or anxiety, castration/ or catastrophization/ or dental anxiety/ or performance anxiety/

17 anxiety disorders/ or agoraphobia/ or anxiety, separation/ or neurocirculatory asthenia/ or neurotic disorders/ or obsessive-compulsive disorder/ or hoarding disorder/ or panic disorder/ or phobic disorders/ or phobia, social/
18 anxiety.mp.
19 stress disorders, traumatic/ or battered child syndrome/ or combat disorders/ or psychological trauma/ or stress disorders, post-traumatic/ or stress disorders, traumatic, acute/
20 obsessive compulsive disorder*.mp.
21 phobia*.mp.
22 psychasthenia.mp.
23 stress disorder*.mp.
24 PTSD.mp.
25 psychotrauma.mp.
26 psychological trauma.mp.
27 behavior, addictive/ or food addiction/
28 substance-related disorders/ or alcohol-related disorders/ or alcohol-induced disorders/ or alcohol-induced disorders, nervous system/ or alcohol amnestic disorder/ or alcoholic korsakoff syndrome/ or alcohol withdrawal delirium/ or alcohol withdrawal seizures/ or alcoholic neuropathy/ or cardiomyopathy, alcoholic/ or fetal alcohol spectrum disorders/ or liver diseases, alcoholic/ or fatty liver, alcoholic/ or hepatitis, alcoholic/ or liver cirrhosis, alcoholic/ or pancreatitis, alcoholic/ or psychoses, alcoholic/ or alcoholic intoxication/ or alcoholism/ or binge drinking/ or wernicke encephalopathy/ or amphetamine-related disorders/ or cocaine-related disorders/ or drug overdose/ or heroin dependence/ or inhalant abuse/ or marijuana abuse/ or neonatal abstinence syndrome/ or opioid-related disorders/ or morphine dependence/ or opium dependence/ or phencyclidine abuse/ or psychoses, substance-induced/ or substance abuse, intravenous/ or substance abuse, oral/ or substance withdrawal syndrome/ or "tobacco use disorder"/
29 addict*.mp.
30 dependen*.mp.
31 "substance use".mp.
32 misus*.mp.
33 abuse*.mp.
34 abusing.mp.
35 Addiction Medicine/
36 withdrawal*.mp.
37 or/9-36
38 8 and 37